Top ▲

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Interleukin 13 receptor, α2

Click here for help

Immunopharmacology Ligand target has curated data in GtoImmuPdb

Target id: 1701

Nomenclature: Interleukin 13 receptor, α2

Family: IL-2 receptor family

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 380 Xq23 IL13RA2 interleukin 13 receptor subunit alpha 2
Mouse 1 383 X 68.46 cM Il13ra2 interleukin 13 receptor, alpha 2
Rat 1 385 Xq34 Il13ra2 interleukin 13 receptor subunit alpha 2
Previous and Unofficial Names Click here for help
interleukin 13 receptor | cancer/testis antigen 19 | CD213a2 | CT19 | IL13BP | IL-13RA2 | IL-13 receptor alpha-2 | IL-13R subunit alpha-2
Database Links Click here for help
Alphafold
CATH/Gene3D
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Gene
OMIM
Pharos
UniProtKB
Wikipedia
Immunopharmacology Comments
Interleukin 13 receptor, α2 acts as a high affinity decoy receptor for interleukin 13 that sequesters the ligand away from IL13Rα1 and is involved in down-regulating IL-13 responses in vivo. IL13ra2 null mice exhibit enhanced IL-13 responses [4].
Increased expression of IL13Rα2 has been reported to promote tumor progression in glioma and other tumor models, and its expression is a prognostic marker for glioma malignancy grade and for poor patient survival [1,3]. This receptor has not been detected on normal brian tissue, making IL13Rα2 a novel selective drug target that has been intensively investigated for the treatment of glioblastoma, with several immunotherapeutic candidates advancing to clinical trial (reviewed in [2]).
Immuno Process Associations
Immuno Process:  B cell (activation)
GO Annotations:  Associated to 1 GO processes, IEA only
click arrow to show/hide IEA associations
GO:0016064 immunoglobulin mediated immune response IEA
Immuno Process:  Cellular signalling
GO Annotations:  Associated to 1 GO processes, IEA only
click arrow to show/hide IEA associations
GO:0043305 negative regulation of mast cell degranulation IEA
Immuno Process:  Cytokine production & signalling
GO Annotations:  Associated to 3 GO processes
GO:0004896 cytokine receptor activity IDA
GO:0019221 cytokine-mediated signaling pathway IBA
GO:0035772 interleukin-13-mediated signaling pathway IDA
Immuno Process:  Immune regulation
GO Annotations:  Associated to 2 GO processes, IEA only
click arrow to show/hide IEA associations
GO:0002638 negative regulation of immunoglobulin production IEA
GO:0043305 negative regulation of mast cell degranulation IEA
Immuno Process:  Inflammation
GO Annotations:  Associated to 1 GO processes, IEA only
click arrow to show/hide IEA associations
GO:0043305 negative regulation of mast cell degranulation IEA
Immuno Process:  T cell (activation)
GO Annotations:  Associated to 1 GO processes, IEA only
click arrow to show/hide IEA associations
GO:0016064 immunoglobulin mediated immune response IEA

References

Show »

1. Debinski W, Gibo DM, Hulet SW, Connor JR, Gillespie GY. (1999) Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin Cancer Res, 5 (5): 985-90. [PMID:10353730]

2. Sengupta S, Thaci B, Crawford AC, Sampath P. (2014) Interleukin-13 receptor alpha 2-targeted glioblastoma immunotherapy. Biomed Res Int, 2014: 952128. [PMID:25247196]

3. Tu M, Wange W, Cai L, Zhu P, Gao Z, Zheng W. (2016) IL-13 receptor α2 stimulates human glioma cell growth and metastasis through the Src/PI3K/Akt/mTOR signaling pathway. Tumour Biol, 37 (11): 14701-14709. [PMID:27623944]

4. Wood N, Whitters MJ, Jacobson BA, Witek J, Sypek JP, Kasaian M, Eppihimer MJ, Unger M, Tanaka T, Goldman SJ et al.. (2003) Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor alpha 2. J Exp Med, 197 (6): 703-9. [PMID:12642602]

How to cite this page

IL-2 receptor family: Interleukin 13 receptor, α2. Last modified on 10/04/2017. Accessed on 20/06/2025. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1701.